{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:28:35Z","timestamp":1774679315957,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ctro.2026.101129","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:40:36Z","timestamp":1771375236000},"page":"101129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Kinetics of prostate volume reduction under hormonal treatment: Timing and impact on external beam radiotherapy \u2013 A PRISMA-Compliant systematic review"],"prefix":"10.1016","volume":"58","author":[{"given":"Youssef","family":"Ghannam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8496-6918","authenticated-orcid":false,"given":"Mario","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5374-8851","authenticated-orcid":false,"given":"V\u00e9rane","family":"Achard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101129_b0005","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2026.101129_b0015","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.ctro.2026.101129_b0020","article-title":"What is the pathophysiology of a hormone-resistant prostate tumour?","volume":"47","author":"Tombal","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctro.2026.101129_b0025","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0360-3016(99)00069-3","article-title":"American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer","volume":"44","author":"Nag","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101129_b0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.radonc.2019.08.027","article-title":"ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer","volume":"141","author":"Ghadjar","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0040","article-title":"Hypofractionation Adoption in Prostate Cancer Radiotherapy: results of an International Survey","volume":"9","author":"Sabbagh","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12020574","article-title":"Using a further Planning MRI after Neoadjuvant Androgen Deprivation Therapy significantly Reduces the Radiation Exposure of Organs at risk in External Beam Radiotherapy of Prostate Cancer","volume":"12","author":"Merten","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctro.2026.101129_b0050","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/jrr\/rrae056","article-title":"Impact of neoadjuvant androgen deprivation therapy on toxicity in intensity-modulated radiation therapy for prostate cancer","volume":"65","author":"Serizawa","year":"2024","journal-title":"J Radiat Res"},{"key":"10.1016\/j.ctro.2026.101129_b0055","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.prro.2024.05.009","article-title":"Urinary Organs at risk for Prostate Cancer External Beam Radiation Therapy: Contouring guidelines on Behalf of the Francophone Group of Urological Radiation Therapy","volume":"14","author":"Le Gu\u00e9velou","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0060","doi-asserted-by":"crossref","unstructured":"Draulans C, Haustermans K, Pos FJ, van der Heide UA, De Cock L, van der Voort van Zyp J, et al. Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial. Radiother Oncol. 2024;201:110568.","DOI":"10.1016\/j.radonc.2024.110568"},{"key":"10.1016\/j.ctro.2026.101129_b0065","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the Intraprostatic Tumor in External Beam Radiotherapy for patients with Localized Prostate Cancer: results from the FLAME Randomized phase III Trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0070","first-page":"523","article-title":"Neoadjuvant hormonal deprivation before radical prostatectomy","volume":"16","author":"Schulman","year":"1993","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.ctro.2026.101129_b0075","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0360-3016(99)00119-4","article-title":"The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate","volume":"44","author":"Whittington","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101129_b0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/pros.2990220106","article-title":"The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia","volume":"22","author":"Tempany","year":"1993","journal-title":"Prostate"},{"key":"10.1016\/j.ctro.2026.101129_b0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000475053","article-title":"Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate","volume":"28","author":"Voges","year":"1995","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2026.101129_b0090","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2214\/ajr.166.5.8615261","article-title":"Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging","volume":"166","author":"Chen","year":"1996","journal-title":"AJR Am J Roentgenol"},{"issue":"Suppl 1","key":"10.1016\/j.ctro.2026.101129_b0095","article-title":"Effects of neoadjuvant androgen deprivation therapy on prostatic cancer","volume":"30","author":"Polito","year":"1996","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.ctro.2026.101129_b0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000282861","article-title":"Effects of androgen deprivation prior to radical prostatectomy in 375 patients","volume":"56","author":"Tunn","year":"1996","journal-title":"Urol Int"},{"key":"10.1016\/j.ctro.2026.101129_b0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0167-8140(00)00219-X","article-title":"Computed tomography\/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation","volume":"57","author":"Lilleby","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0110","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/S0022-5347(05)65001-X","article-title":"Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy","volume":"167","author":"Kucway","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ctro.2026.101129_b0115","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0936-6555(03)00093-1","article-title":"Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? a prospective, observational study","volume":"15","author":"Henderson","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ctro.2026.101129_b0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00130404-200405000-00008","article-title":"The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy","volume":"10","author":"Merrick","year":"2004","journal-title":"Cancer J"},{"key":"10.1016\/j.ctro.2026.101129_b0125","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijrobp.2005.06.035","article-title":"The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy","volume":"64","author":"Niehaus","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101129_b0130","first-page":"335","article-title":"The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer","volume":"61","author":"Ebara","year":"2007","journal-title":"Acta Med Okayama"},{"key":"10.1016\/j.ctro.2026.101129_b0135","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.urolonc.2007.05.014","article-title":"Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity","volume":"26","author":"Petit","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0140","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.brachy.2007.08.007","article-title":"Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume","volume":"6","author":"Petit","year":"2007","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ctro.2026.101129_b0145","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1148\/radiology.218.2.r01ja04365","article-title":"Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging","volume":"218","author":"Padhani","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.ctro.2026.101129_b0150","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.urolonc.2009.03.024","article-title":"Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy","volume":"29","author":"Langenhuijsen","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0155","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1111\/j.1464-410X.2012.11107.x","article-title":"Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide","volume":"110","author":"Axcrona","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ctro.2026.101129_b0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/00365599.2011.637953","article-title":"Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: a long-term prospective study","volume":"46","author":"Klarskov","year":"2012","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.ctro.2026.101129_b0165","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.prro.2012.10.004","article-title":"Anatomic variation and dosimetric consequences of neoadjuvant hormone therapy before radiation therapy for prostate cancer","volume":"3","author":"Melancon","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0170","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.clon.2012.09.010","volume":"25","author":"Mason","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ctro.2026.101129_b0175","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000345423","article-title":"Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233)","volume":"90","author":"Anderson","year":"2013","journal-title":"Urol Int"},{"key":"10.1016\/j.ctro.2026.101129_b0180","doi-asserted-by":"crossref","DOI":"10.2214\/AJR.13.12277","article-title":"Diffusion-weighted imaging to evaluate for changes from androgen deprivation therapy in prostate cancer","volume":"203","author":"Kim","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ctro.2026.101129_b0185","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1007\/s00330-015-3688-1","article-title":"Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI","volume":"25","author":"H\u00f6tker","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ctro.2026.101129_b0190","doi-asserted-by":"crossref","first-page":"342","DOI":"10.5213\/inj.1632628.314","article-title":"The Influence of Androgen Deprivation Therapy on Prostate size and Voiding Symptoms in Prostate Cancer patients in Korea","volume":"20","author":"Choi","year":"2016","journal-title":"Int Neurourol J"},{"key":"10.1016\/j.ctro.2026.101129_b0195","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/luts.12142","article-title":"Impact of Androgen Deprivation Therapy on volume Reduction and lower Urinary Tract Symptoms in patients with Prostate Cancer","volume":"10","author":"Washino","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.ctro.2026.101129_b0200","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.brachy.2017.12.005","article-title":"A phase II trial of 8weeks of degarelix for prostate volume reduction: Efficacy and hormonal recovery","volume":"17","author":"Korzeniowski","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ctro.2026.101129_b0205","article-title":"Lower urinary tract symptoms in patients with prostate cancer under and after intensity-modulated radiation therapy","volume":"11","author":"Hayama","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.ctro.2026.101129_b0210","first-page":"157","article-title":"Effect of hormonal therapy for volume reduction, lower urinary tract symptom relief and voiding symptoms in prostate cancer: leuprolide vs goserelin","volume":"16","author":"Yikilmaz","year":"2019","journal-title":"Urol J"},{"key":"10.1016\/j.ctro.2026.101129_b0215","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/1754-9485.13017","volume":"64","author":"Christie","year":"2020","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0220","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2020.03.001","volume":"78","author":"Dearnaley","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2026.101129_b0225","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.phro.2021.01.004","article-title":"Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy","volume":"17","author":"Bj\u00f6reland","year":"2021","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2021.12.020","article-title":"Changes in magnetic Resonance Imaging Radiomic Features in Response to Androgen Deprivation Therapy in patients with Intermediate- and High-risk Prostate Cancer","volume":"34","author":"Tharmalingam","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ctro.2026.101129_b0235","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ijrobp.2024.11.010","volume":"121","author":"Fukuokaya","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101129_b0240","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.22.00970","article-title":"Sequencing of Androgen-Deprivation Therapy of Short Duration with Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): a Pooled Analysis of 12 Randomized Trials","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0245","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.prro.2023.09.007","article-title":"Radiation Therapy Summary of the AUA\/ASTRO Guideline on Clinically Localized Prostate Cancer","volume":"14","author":"Deville","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109544","article-title":"ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer","volume":"183","author":"Schmidt-Hegemann","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0255","doi-asserted-by":"crossref","first-page":"243","DOI":"10.32604\/cju.2025.066700","article-title":"National survey of radiotherapy and androgen deprivation therapy strategies with PSMA-PET\/CT integration in intermediate-risk prostate cancer: TROD 09-007 study","volume":"32","author":"Elmali","year":"2025","journal-title":"Can J Urol"},{"key":"10.1016\/j.ctro.2026.101129_b0260","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clgc.2015.12.005","article-title":"Radiotherapy boost for the Dominant Intraprostatic Cancer Lesion-a Systematic Review and Meta-Analysis","volume":"14","author":"von Eyben","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ctro.2026.101129_b0265","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(25)00205-0","article-title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","volume":"26","author":"Tree","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0270","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1748-717X-9-22","article-title":"Change in prostate volume during extreme hypo-fractionation analysed with MRI","volume":"9","author":"Gunnlaugsson","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2026.101129_b0275","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.eururo.2024.10.026","article-title":"Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial","volume":"87","author":"Kishan","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2026.101129_b0280","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000356272","article-title":"Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis","volume":"93","author":"Cui","year":"2014","journal-title":"Urol Int"},{"key":"10.1016\/j.ctro.2026.101129_b0285","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/luts.12114","article-title":"Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of lower Urinary Tract Symptoms in Prostate Cancer patients: results of a Pooled Analysis","volume":"9","author":"Mason","year":"2017","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.ctro.2026.101129_b0290","doi-asserted-by":"crossref","first-page":"371","DOI":"10.5114\/jcb.2016.63377","article-title":"Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression","volume":"8","author":"Jethwa","year":"2016","journal-title":"J Contemp Brachytherapy"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826000248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826000248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:25:49Z","timestamp":1774671949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826000248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":58,"alternative-id":["S2405630826000248"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101129","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kinetics of prostate volume reduction under hormonal treatment: Timing and impact on external beam radiotherapy \u2013 A PRISMA-Compliant systematic review","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101129"}}